SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: Cbdpotential
Search This Board: 
Last Post: 4/28/2017 5:46:32 PM - Followers: 160 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
SureTrader
IDRA News: Proxy Statement (definitive) (def 14a) 04/28/2017 05:08:03 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 04/26/2017 06:00:27 PM
IDRA News: Current Report Filing (8-k) 04/18/2017 04:15:40 PM
IDRA News: Idera Pharmaceuticals Announces Organizational Update 04/18/2017 04:01:00 PM
IDRA News: Confidential Treatment Order (ct Order) 04/13/2017 09:07:58 AM
PostSubject
#2889   Annual SH meeting. Citrati 04/28/17 05:46:32 PM
#2888   Your comments are helpful. Thanks... Stockdoggy 04/27/17 06:58:32 AM
#2887   Pillar actually, sold 437,829 Monday and 890,593 on Citrati 04/26/17 07:08:06 PM
#2886   Very good response and I do agree, in Farmmarket1 04/26/17 06:29:20 PM
#2885   At least for the time being, IMO, 1.3million Citrati 04/26/17 06:26:00 PM
#2884   Pillar dumped 1.3 mil today... what does Farmmarket1 04/26/17 06:07:57 PM
#2883   IDRA is a great example of knowing the Citrati 04/26/17 05:39:48 PM
#2882   Nice day today. Up 8% on high Stockdoggy 04/25/17 04:12:27 PM
#2881   Thanks stockdoggy. Not as high as previous attilathehunt 04/25/17 08:36:15 AM
#2880   I will take whatever keeps positive focus on Citrati 04/25/17 08:05:12 AM
#2879   Baird initiates coverage of IDRA with Outperform rating Stockdoggy 04/25/17 05:52:08 AM
#2878   I couldn't find any news that would explain attilathehunt 04/24/17 11:58:35 PM
#2877   What I find significant is that on Feb Citrati 04/15/17 01:52:49 PM
#2876   March 15, 2020 Cbdpotential 04/15/17 03:08:16 AM
#2875   If I'm not mistaken this is the second Farmmarket1 04/14/17 05:05:38 AM
#2874   Thanks as well! Radar_Mi 04/13/17 02:35:02 PM
#2873   It is a "Confidential Treatment" order. It nsomniyak 04/13/17 02:31:05 PM
#2872   Thanks Radar_Mi 04/13/17 01:35:02 PM
#2871   I didn't say anything about excitement. I attilathehunt 04/13/17 01:16:44 PM
#2870   Confidential Treatment attilathehunt 04/13/17 01:14:36 PM
#2869   Excuse me but as foreign investor I'm not Radar_Mi 04/13/17 01:06:26 PM
#2868   CT orders happen all the time in the nsomniyak 04/13/17 11:47:44 AM
#2867   Hummm CT order...Last time I saw this happen attilathehunt 04/13/17 09:28:49 AM
#2866   Long And Holding $IDRA Cbdpotential 04/06/17 11:35:05 AM
#2865   Citrati - thanks for the chart! Nine block attilathehunt 04/05/17 05:00:04 PM
#2864   2.24 is the bb midline on a daily. Citrati 04/05/17 03:08:11 PM
#2863   https://www.thestreet.com/story/14074006/1/idera-pharmaceuticals-presents-clinic Citrati 04/05/17 11:28:22 AM
#2862   $IDRA. Positive clinical news today!!! I am long. BusterCWK 04/05/17 08:07:55 AM
#2861   "Could IDRA be sitting on a blockbuster?" Citrati 03/26/17 10:13:55 PM
#2860   Could Idera Pharmaceuticals Inc (NASDAQ:IDRA) Be Sitting On usasingh1 03/25/17 01:11:27 AM
#2859   Here is the 3 year weekly perspective and Citrati 03/23/17 12:27:20 AM
#2858   Feeling good here Stay green my friend ;-) Cbdpotential 03/22/17 11:19:16 PM
#2857   ;-) $IDRA Cbdpotential 03/22/17 10:53:23 PM
#2856   * * $IDRA Video Chart 03-22-17 * * ClayTrader 03/22/17 04:41:48 PM
#2855   Congrats everyone. We will have our ups and Citrati 03/22/17 10:02:19 AM
#2854   JMP Securities initiated at Outperform w/$8 price target. Cre8tivmynd 03/22/17 09:13:03 AM
#2853   Doc7 who upgraded it?? the gipper 03/22/17 09:06:49 AM
#2852   Upgraded to outperform doc7 03/22/17 08:41:39 AM
#2850   Very nice day today. :-D :-D Citrati 03/20/17 03:05:08 PM
#2848   just google it. Pretty simple. Shows the success kld2 03/20/17 05:50:10 AM
#2847   91% fails where did you get this information youssef 03/19/17 11:35:02 PM
#2846   Well I did something I never did before attilathehunt 03/17/17 07:58:02 PM
#2845   Love this post! Go $IDRA Cbdpotential 03/17/17 02:42:38 PM
#2844   :-D Two thumbs up. Citrati 03/16/17 01:44:05 PM
#2843   Why is IDERA different from other biotechs with kld2 03/16/17 07:56:44 AM
#2842   Nice ER!!! homdance 03/15/17 06:14:19 PM
#2841   As long as science continues progressing price movement Citrati 03/06/17 11:16:36 PM
#2840   Been apart of many, many head fakes and Farmmarket1 03/06/17 08:54:20 AM
#2839   I generally don't post when I have no chmcnfunds 03/06/17 07:48:57 AM
#2838   Just need to cool down a little. Get Citrati 03/05/17 11:24:16 PM
PostSubject